CUPR vs STRO: stock comparison

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste; and products using medical leeches for wound treatment. The company was founded in 2019 and is based in Singapore. Cuprina Holdings (Cayman) Limited operates as a subsidiary of Cuprina Holding Pte. Ltd.

Open CUPR dashboard ↗

Sutro Biopharma, Inc.

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Open STRO dashboard ↗

CUPR vs STRO

Compare the businesses

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

Sutro Biopharma, Inc.

Sign in to keep comparing stocks